| P50 | author | Ian F. Tannock | Q106114426 |
| P2093 | author name string | Malcolm J Moore | |
| | Helen G Juffs | |
| P2860 | cites work | Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study | Q28139358 |
| | Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group | Q33330628 |
| | Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial | Q33331273 |
| | Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer | Q33426977 |
| | Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group | Q33488031 |
| | Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma | Q33499366 |
| | Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer | Q33500776 |
| | Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer | Q33501053 |
| | A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer | Q33504597 |
| | Identification of p53 gene mutations in bladder cancers and urine samples | Q34104561 |
| | Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors | Q34343325 |
| | A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced B | Q36115630 |
| | Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients | Q36115695 |
| | Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter | Q36116031 |
| | The management of invasive bladder cancer: a review of selected Australasian studies in radiotherapy, chemotherapy and cystectomy | Q37663667 |
| | Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens | Q38460001 |
| | Chemotherapy in the management of bladder tumours | Q38679784 |
| | Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study | Q40625649 |
| | A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 |
| | Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. | Q40787956 |
| | Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience | Q43806537 |
| | The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial | Q45146420 |
| | Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group | Q45263554 |
| | Accumulation of nuclear p53 and tumor progression in bladder cancer. | Q45977663 |
| | A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract | Q46565121 |
| | Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the Bladder | Q59392031 |
| | Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience | Q61897468 |
| | Advanced Bladder Cancer (Stages pT3b, pT4a, pN1 and pN2): Improved Survival after Radical Cystectomy and 3 Adjuvant Cycles of Chemotherapy. Results of a Controlled Prospective Study | Q68215944 |
| | Adjuvant chemotherapy of bladder cancer: a preliminary report | Q68372731 |
| | A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 |
| | Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial | Q68945079 |
| | Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract | Q69886661 |
| | Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy | Q70113435 |
| | Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report | Q70243006 |
| | A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study | Q70268069 |
| | Adjuvant Chemotherapy with Doxorubicin (Adriamycin) and 5-Fluorouracil in T3, NX, MO Bladder Cancer Treated with Radiotherapy | Q70274247 |
| | Prognostic indices for bladder cancer: an analysis of patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage X-ray therapy | Q70324866 |
| | Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12 | Q70670936 |
| | Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group | Q71050273 |
| | Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group study | Q71228627 |
| | Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy | Q71536563 |
| | Concurrent radiation and cisplatin in the treatment of advanced bladder cancer: a preliminary report | Q71635318 |
| | Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression | Q72066713 |
| | Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC | Q72240687 |
| | Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial | Q72506070 |
| | Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced Bladder Cancer Overview Collaboration | Q72531493 |
| | Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I | Q72730237 |
| | Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q73494793 |
| | Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer | Q73719687 |
| | Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European | Q73881573 |
| | Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC | Q74619157 |
| | Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03 | Q77562027 |
| | Pelvic lymph node dissection can be curative in patients with node positive bladder cancer | Q77895651 |
| | Stat bite: U.S. urinary bladder cancer death rates | Q78140486 |
| | Uncertainty and outcome of invasive bladder tumors | Q83169234 |
| | Combined radiation and chemotherapy for locally advanced transitional cell carcinoma of the urinary bladder | Q93606577 |
| P433 | issue | 12 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 738-747 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | The role of systemic chemotherapy in the management of muscle-invasive bladder cancer | |
| P478 | volume | 3 | |